Maintenance drug after stem cell transplant for Ph+ ALL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted pill (olverembatinib) given after a stem cell transplant to help prevent leukemia from coming back in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It may also be used early if signs of the disease appear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Ph+ ALL (a type of leukemia with a specific gene change).
- You had a stem cell transplant (from a donor) and are at least 30 days past the transplant.
- You are 18 years or older.
- Your liver and kidney function are within acceptable limits.
- You are not infected with HIV, hepatitis B, or hepatitis C.
- You are physically able to be up and about (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs given before a stem cell transplant for people with a specific type of acute lymphoblastic leukemia (Ph+ ALL) that did not fully respond to initial treatment. The goal is to make the leukemia undetectable before transplant, which may improve outcomes.
This trial tests whether adding the drug asciminib to standard care after a stem cell transplant can help keep certain types of leukemia from coming back. Asciminib is a type of targeted therapy that blocks a specific protein driving the cancer.
This trial combines a targeted antibody therapy with a low dose of chemotherapy to treat adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combo can help shrink or eliminate the leukemia with fewer side effects than standard treatment.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial tests two medicines together: olverembatinib (a pill) and blinatumomab (given by infusion). It is for people who are newly diagnosed with Ph+ ALL and have not had chemotherapy yet. The goal is to see if this combination works well and is safe.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.